Chemours (NYSE:CC – Free Report) had its target price reduced by Barclays from $40.00 to $31.00 in a report issued on Wednesday morning, Marketbeat Ratings reports. They currently have an equal weight rating on the specialty chemicals company’s stock. Several other equities research analysts have also weighed in on CC. BMO Capital Markets lowered their […]
The Chemours Company (NYSE:CC – Free Report) – Equities researchers at Zacks Research reduced their Q3 2023 earnings per share (EPS) estimates for shares of Chemours in a note issued to investors on Thursday, September 28th. Zacks Research analyst A. Barman now expects that the specialty chemicals company will earn $0.82 per share for the […]
Crescent Grove Advisors LLC acquired a new position in The Chemours Company (NYSE:CC – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 5,500 shares of the specialty chemicals company’s stock, valued at approximately $203,000. Other institutional investors and hedge funds have […]
The Chemours Company (NYSE:CC – Get Free Report) was the recipient of a significant drop in short interest in August. As of August 31st, there was short interest totalling 4,840,000 shares, a drop of 10.4% from the August 15th total of 5,400,000 shares. Currently, 3.3% of the shares of the stock are sold short. Based […]
The Chemours Company (NYSE:CC – Get Free Report) has been given a consensus recommendation of “Hold” by the ten research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and two have given a buy recommendation to the company. The […]